Lates News

According to a report released by Cinda Securities on September 2, Sanxiang Biology (688289.SH) has been given a buy rating. The main reasons for the rating include: 1) The consolidation of Haiji will enhance performance, and traditional diagnostic business is expected to return to a fast-growing track; 2) Investment and mergers empower, and the pattern of "diagnosis + treatment" dual-drive is preliminarily formed. (Daily Economic News)